ACAD enters its August 6 earnings report with the Street raising targets on the same day the stock gained 6%, a rare confluence that sharpens the focus on what management says next.
The analyst moves this week tell a consistent story: the direction is up. Three firms raised price targets on August 5 alone — RBC Capital moved to $37, Citizens to $36, and Oppenheimer to $25. The raises follow a broader trend that has seen virtually every firm with an active rating lift its target over the past six weeks. BofA, Citigroup, Canaccord, and BMO Capital all moved higher between late June and late July. The mean price target now stands at $33.25, roughly 22% above the August 4 close of $27.15. The split in conviction remains, though: most firms cluster in the $35–$37 range, while Oppenheimer and Stifel sit at $25, reflecting a genuine debate between those buying the neurological pipeline story and those waiting for commercial execution proof. The bull case rests on the HARMONY O45 data in dementia-related psychosis and the Parkinson's subgroup read-through. Bears point to pimavanserin's chequered history in additional indications and Daybue's slow commercial build.
Short positioning has shifted materially over the past month, and the borrow market confirms bears are not rebuilding. Short interest has dropped 30% in a month, from roughly 14.5 million shares in late June to 10.2 million now — 6% of the free float, down from above 8.5% at the July peak. Availability has loosened dramatically: at nearly 2,961% of outstanding short interest, there are roughly 166 million shares available to borrow against 10 million already lent. Cost to borrow remains negligible at 0.50%, down 11% on the week. The lending market is as relaxed as it has been all year, which means no mechanical squeeze pressure is building from that side. Options reinforce the constructive read: the put/call ratio is 0.26, near its 52-week low of 0.20, and well below the 20-day average of 0.28. Call demand is running well above normal relative to put protection — unusual ahead of an event that historically caused the stock to barely move (the May 2026 print produced a day-one decline of just 0.5%).
The ownership picture adds texture to the bullish skew. Baker Bros. Advisors, a specialist biotech fund known for concentrated long-term bets, holds 25% of shares outstanding — a figure that effectively anchors the register. BlackRock added 795,000 shares through June, and State Street added 579,000. On the insider side, an EVP sold roughly $430,000 of stock on July 30 following a routine equity award — low significance scores and standard post-award disposal, not a directional signal. The ORTEX short score has eased from 51.7 a week ago to 49.3, drifting into neutral territory and consistent with the broader short unwind story.
The August 6 print is now the single variable the positioning narrative cannot pre-answer: shorts have retreated, options traders are tilted long, and analysts have spent a month hiking targets — so the question is whether the earnings release gives them a reason to stay there.
See the live data behind this article on ORTEX.
Open ACAD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
